+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study



Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study



Arthritis and Rheumatism 48(10): 2763-2768



To assess the safety of tacrolimus used in combination with oral methotrexate (MTX) to control the signs and symptoms of rheumatoid arthritis (RA) in patients whose disease remains active despite treatment with MTX. This was a multicenter open-label study conducted at 13 US sites. Eighty patients who at baseline had active RA (mean tender/painful joint count 29.4, mean swollen joint count 17.4, mean erythrocyte sedimentation rate 25.1 mm/hour) despite treatment for >/=1 month with a stable, maximally tolerated dosage of oral MTX (/=30% maximum increase in the Cr level from baseline during the study, with the Cr level in 3 patients (3.8%) exceeding the range considered normal for their age and sex. The maximum Cr level during the study was 1.8 mg/dl. The ACR20 clinical response rate at the end of treatment was 52.5% (95% confidence interval 41.6-63.4%). In patients whose active RA persists despite treatment with MTX, tacrolimus in combination with MTX is safe and well-tolerated and provides clinical benefit.

(PDF emailed within 0-6 h: $19.90)

Accession: 050497710

Download citation: RISBibTeXText

PMID: 14558080

DOI: 10.1002/art.11257


Related references

Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study. Clinical Therapeutics 34(1): 77-90, 2012

Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study. Annals of the Rheumatic Diseases 67(8): 1090-1095, 2007

Phase I/II open-label trial of DAB-389IL-2 administered to patients with active rheumatoid arthritis receiving treatment with methotrexate. Arthritis & Rheumatism 37(9 SUPPL ): S341, 1994

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis and Rheumatism 65(3): 559-570, 2013

Traditional herbal medicines for patients with rheumatoid arthritis receiving concomitant methotrexate a preliminary study. Alternative Therapies In Health And Medicine: 1, 46-51, 2010

Traditional herbal medicines (Kampo) for patients with rheumatoid arthritis receiving concomitant methotrexate: a preliminary study. Alternative Therapies in Health and Medicine 16(1): 46-51, 2010

Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis and Rheumatism 46(8): 2020-2028, 2002

Safety of long-term tacrolimus therapy for rheumatoid arthritis: an open-label, uncontrolled study in non-elderly patients. Modern Rheumatology 18(4): 345-353, 2008

Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate. Annals of the Rheumatic Diseases 67(11): 1648-1649, 2008

Methotrexate therapy of rheumatoid arthritis. An open observation study of 110 patients with median length of treatment of 17.8 month. Ugeskrift for Laeger 155(30): 2323-2327, 1993

Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use. Rheumatology International 35(10): 1707-1716, 2016

Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Research & Therapy 18(): 34-34, 2016

Minimal efficacy of a depleting chimeric anti-CD4 in treatment of patients with refractory rheumatoid arthritis receiving concomitant methotrexate. Arthritis & Rheumatism 36(9 SUPPL ): S39, 1993

Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study. Modern Rheumatology 24(5): 725-733, 2015

Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. Arthritis Care & Research 65(5): 718-728, 2013